Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been assigned an average recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $76.20.

Several research firms recently issued reports on BGNE. Zacks Investment Research raised shares of BeiGene from a “sell” rating to a “buy” rating and set a $79.00 price objective for the company in a report on Tuesday, July 11th. Ladenburg Thalmann Financial Services began coverage on shares of BeiGene in a report on Monday, August 7th. They set a “buy” rating and a $81.00 price objective for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $83.00 price objective on shares of BeiGene in a report on Monday, July 10th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $86.00 price objective (up from $43.00) on shares of BeiGene in a report on Tuesday, August 15th. Finally, Maxim Group upped their price objective on shares of BeiGene from $57.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, July 7th.

BeiGene (BGNE) traded up 8.91% during midday trading on Tuesday, reaching $75.06. 294,818 shares of the company traded hands. The firm has a 50 day moving average of $71.93 and a 200-day moving average of $48.93. The stock’s market capitalization is $2.99 billion. BeiGene has a 12 month low of $26.43 and a 12 month high of $79.89.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/01/beigene-ltd-bgne-receives-76-20-consensus-pt-from-analysts.html.

In other BeiGene news, Director Xiaodong Wang sold 35,000 shares of the stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $44.95, for a total value of $1,573,250.00. Following the completion of the sale, the director now directly owns 26,600 shares of the company’s stock, valued at approximately $1,195,670. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 176,056 shares of BeiGene stock in a transaction on Friday, August 11th. The stock was bought at an average cost of $71.00 per share, with a total value of $12,499,976.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 383,710 shares of company stock valued at $22,373,260. Insiders own 24.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its position in shares of BeiGene by 2.5% in the second quarter. The Manufacturers Life Insurance Company now owns 94,933 shares of the company’s stock worth $4,272,000 after buying an additional 2,300 shares in the last quarter. State Street Corp boosted its position in shares of BeiGene by 14.4% in the second quarter. State Street Corp now owns 36,604 shares of the company’s stock worth $1,647,000 after buying an additional 4,619 shares in the last quarter. Hillhouse Capital Management Ltd. boosted its position in shares of BeiGene by 172.6% in the second quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock worth $167,433,000 after buying an additional 2,355,906 shares in the last quarter. Employees Retirement System of Texas acquired a new position in shares of BeiGene during the second quarter worth about $2,855,000. Finally, Parametric Portfolio Associates LLC boosted its position in shares of BeiGene by 25.0% in the second quarter. Parametric Portfolio Associates LLC now owns 13,496 shares of the company’s stock worth $607,000 after buying an additional 2,700 shares in the last quarter. Institutional investors own 51.02% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.